Regulatory T cell induction via short-chain fatty acid (butyrate) stimulation

Regulatory T cell induction via short-chain fatty acid/butyrate stimulation refers to the promotion of regulatory T cell (Treg) differentiation and function by microbial metabolites known as short-chain fatty acids, particularly butyrate. Butyrate is produced in the colon through bacterial fermentation of dietary fibers. It exerts its immunomodulatory effects primarily through two mechanisms: 1. Inhibition of histone deacetylases (HDACs): This leads to increased histone acetylation and changes in gene expression that favor the development and suppressive function of regulatory T cells[2][4][5][7]. 2. Activation of G protein-coupled receptors: Notably GPR109A on dendritic cells and possibly GPR43 on epithelial or immune cells; these pathways contribute to anti-inflammatory signaling cascades[1][2]. Butyrate can act directly on naïve CD4+ T cells under transforming growth factor β–based conditions to enhance their differentiation into induced regulatory T cells with potent suppressive capacity[3][5][7]. It also acts indirectly by conditioning dendritic cells toward a tolerogenic phenotype that promotes IL‑10–producing type 1 regulatory T cell responses[1]. The effect is context-dependent—at certain concentrations butyrate may also induce pro-inflammatory molecules such as IFN‑γ during early stages of differentiation[3]. This pathway plays an important role in maintaining intestinal homeostasis, controlling inflammation, preventing autoimmunity, and potentially modulating neuroinflammatory processes via gut-brain communication. However, it does not represent a single molecular entity or classic "therapeutic target" like an enzyme or receptor; rather it describes an immunoregulatory mechanism involving multiple cellular players influenced by microbial metabolites. Because "Regulatory T cell induction via SCFA/butyrate stimulation" describes a complex biological process—not one specific molecule/receptor—it should not be considered a canonical therapeutic target per se. Instead, it represents an emerging area for therapeutic modulation using dietary interventions or microbiome-based strategies aimed at increasing endogenous production of beneficial SCFAs such as butyrate[4][5][7].

Other names

SCFA-induced regulatory T cell differentiationButyrate-mediated Treg inductionShort-chain fatty acid–Treg axis